BioDuro published an article introducing its in vivo MASH platform, validating the 24-week high-fat diet-induced obesogenic mouse model using resmetirom, tirzepatide, and efruxifermin across distinct mechanisms of action and characterized by low variability and robust liver fibrosis.
Published
Signal category
Research & Knowledge
Quote
“This article introduces BioDuro’s in vivo MASH platform. The 24-week, high-fat diet (HFD)-induced obesogenic mouse model has been validated using resmetirom, tirzepatide, and efruxifermin across distinct mechanisms of action and is characterized by low variability and robust liver fibrosis.”
— BioDuro team
Company
BioDuro
Your Global CRDMO, Rooted in Science
- Industry
- Pharmaceutical Manufacturing
- Location
- Irvine, US
- Company size
- 474 employees
BioDuro, an Advent portfolio company, is a CRDMO with a 30-year proven track record. Headquartered in Irvine, California, BioDuro employs more than 2,000 scientists with deep expertise in small- and large-molecule discovery, development, and manufacturing. We provide fully integrated drug discovery services spanning chemistry, biology, and pharmacokinetics (DMPK), along with comprehensive IND-enabling capabilities, including both drug substance and drug product development. Across 8 sites in mainland China, Taiwan, and the United States. BioDuro supports the innovation needs of clients worldwide. For more information about BioDuro, please visit our website at www.bioduro.com
Founded 1996